Michael Gilman Sells 2,544 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) Director Michael Gilman sold 2,544 shares of Scholar Rock stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the completion of the transaction, the director owned 59,511 shares of the company’s stock, valued at $3,205,857.57. This trade represents a 4.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 2.2%

Shares of SRRK opened at $56.56 on Wednesday. The company has a market capitalization of $6.78 billion, a P/E ratio of -15.75 and a beta of 0.67. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $57.80. The business’s 50 day simple moving average is $48.79 and its 200-day simple moving average is $46.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64.

Get Scholar Rock alerts:

Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the company posted ($0.67) earnings per share. As a group, sell-side analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Institutional Trading of Scholar Rock

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in Scholar Rock by 20.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock valued at $77,000 after purchasing an additional 242 shares during the period. Bank of America Corp DE grew its position in shares of Scholar Rock by 27.2% during the 1st quarter. Bank of America Corp DE now owns 1,336,632 shares of the company’s stock worth $65,709,000 after buying an additional 286,126 shares during the period. Janus Henderson Group PLC raised its stake in shares of Scholar Rock by 26.1% during the first quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company’s stock worth $109,891,000 after buying an additional 462,669 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Scholar Rock by 485.3% during the first quarter. ADAR1 Capital Management LLC now owns 407,273 shares of the company’s stock worth $20,022,000 after buying an additional 337,684 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in Scholar Rock by 23.2% in the first quarter. California State Teachers Retirement System now owns 74,916 shares of the company’s stock valued at $3,683,000 after buying an additional 14,101 shares during the period. 91.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on SRRK. Canaccord Genuity Group started coverage on Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. HC Wainwright upped their target price on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock currently has an average rating of “Buy” and an average target price of $56.00.

Read Our Latest Report on Scholar Rock

About Scholar Rock

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

Featured Articles

• Five stocks we like better than Scholar Rock
• Apple and Broadcom Forge a Decade-Long Silicon Fortress
• SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
• The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
• Palantir’s CEO Just Called Out OpenAI and Anthropic

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.